Published on February 9, 2010 at 1:26 AM
GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.
"The HIV/AIDS population continues to grow at an alarming rate, 60,000 new infections annually, and that's just in the United States. Preventing the spread of this disease and controlling infections through the development of vaccines remains our mission and our goal," stated Robert McNally, Ph.D., president and chief executive officer. "On the preventative front, our Phase 2a trial is now enrolling at two locations in Peru where sites were slow to open due to local government review. And we are making good progress with our therapeutic vaccine, as we completed a Pre-IND meeting with the U.S. FDA in December and are well into the process for submission of an IND for a Phase 1 trial. We look forward to discussing this progress with stakeholders at the BIO CEO meeting in New York City tomorrow.
"We have engaged a full-service Clinical Research Organization (CRO) to support our therapeutic human clinical vaccine trials. They will be providing assistance for clinical trial management; clinical, medical and safety monitoring; data management, biostatistics and medical writing services," stated Dr. McNally.
SOURCE GeoVax Labs, Inc.
583be827-9d68-4e11-8384-68ff80752893|0|.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Allergy, Antibody, Antiretroviral, Biotechnology, CDC, Cell, DNA, HIV/AIDS, Immunodeficiency, New Drug Application, Recombinant DNA, RNA, Vaccine, Virus